Axis Business Park
Rue Edouard Belin 2
32 1 039 41 00
|Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME||Co-Founder, CFO, Interim CEO & Director||86,49k||N/A||1956|
|Mr. David Georges||VP of Fin. & Admin.||N/A||N/A||N/A|
|Sara Zelkovic||Communications & Investor Relations Director||N/A||N/A||N/A|
|Mr. Philippe Nobels||Chief HR Officer & VP of HR||N/A||N/A||1966|
|Ms. An Phan||Head of Legal||N/A||N/A||N/A|
|Mr. Hannes Iserentant||Head of Intellectual Property||N/A||N/A||N/A|
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Celyad Oncology SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.